Robert McRae - Palisade Bio VP Devel
| PALI Stock | USD 2.40 0.04 1.64% |
Insider
Robert McRae is VP Devel of Palisade Bio
| Address | 7750 El Camino Real, Carlsbad, CA, United States, 92009 |
| Phone | 858 704 4900 |
| Web | https://www.palisadebio.com |
Palisade Bio Management Efficiency
The company has return on total asset (ROA) of (0.5853) % which means that it has lost $0.5853 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1009) %, meaning that it created substantial loss on money invested by shareholders. Palisade Bio's management efficiency ratios could be used to measure how well Palisade Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.92. The current Return On Capital Employed is estimated to decrease to -1.2. As of now, Palisade Bio's Fixed Asset Turnover is decreasing as compared to previous years. The Palisade Bio's current Asset Turnover is estimated to increase to 0.04, while Total Assets are projected to decrease to under 12.3 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Audrey MD | NovaBay Pharmaceuticals | 65 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Ibrahim MD | Enveric Biosciences | 55 | |
| Yenyou Zheng | NovaBay Pharmaceuticals | 62 | |
| MBA IV | Enveric Biosciences | 68 | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Avani Kanubaddi | Enveric Biosciences | 51 | |
| Covadonga Paeda | Altamira Therapeutics | N/A | |
| Wang Xu | NovaBay Pharmaceuticals | 36 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Peter Facchini | Enveric Biosciences | 60 | |
| Nandan BS | Immix Biopharma | 62 | |
| John CPA | Unicycive Therapeutics | 62 | |
| Justin Esq | NovaBay Pharmaceuticals | 46 | |
| Jean Lechance | Altamira Therapeutics | N/A | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Joseph Tucker | Enveric Biosciences | 55 | |
| DSc MSE | Immix Biopharma | 75 | |
| Swan Sit | NovaBay Pharmaceuticals | 41 | |
| MBA MD | Immix Biopharma | 49 | |
Management Performance
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.59 |
Palisade Bio Leadership Team
Elected by the shareholders, the Palisade Bio's board of directors comprises two types of representatives: Palisade Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Palisade. The board's role is to monitor Palisade Bio's management team and ensure that shareholders' interests are well served. Palisade Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Palisade Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joerg Heyer, Head Medicine | ||
| Ryker Willie, Senior Controller | ||
| J Finley, CEO Director | ||
| Sharon McBrayer, Director Operations | ||
| Mitchell MD, Chief Officer | ||
| Robert McRae, VP Devel | ||
| MD FAAAAI, Chief Officer |
Palisade Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Palisade Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | (4.01 M) | ||||
| Shares Outstanding | 1.33 M | ||||
| Shares Owned By Insiders | 1.88 % | ||||
| Shares Owned By Institutions | 3.57 % | ||||
| Number Of Shares Shorted | 43.11 K | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 14.03 X |
Currently Active Assets on Macroaxis
When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (13.26) | Return On Assets (0.59) | Return On Equity (1.10) |
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.